Premium
Delivery of ROS Generating Anthraquinones Using Reduction‐Responsive Peptide‐Based Nanoparticles
Author(s) -
Richard Pascal U.,
Craciun Ioana,
Gaitzsch Jens,
Weiner Lev,
Palivan Cornelia G.
Publication year - 2018
Publication title -
helvetica chimica acta
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.74
H-Index - 82
eISSN - 1522-2675
pISSN - 0018-019X
DOI - 10.1002/hlca.201800064
Subject(s) - chemistry , hela , peptide , drug delivery , drug , viability assay , doxorubicin , nanoparticle , biophysics , targeted drug delivery , doxorubicin hydrochloride , hek 293 cells , combinatorial chemistry , biochemistry , pharmacology , cell , nanotechnology , receptor , organic chemistry , medicine , materials science , surgery , chemotherapy , biology
In order to limit the side effects associated with antitumor drugs such as doxorubicin, nanosized drug‐delivery systems capable of selectively delivering and releasing the drug in the diseased tissue are required. We describe nanoparticles ( NP s), self‐assembled from a reduction responsive amphiphilic peptide, capable of entrapping high amounts of a redox active anticancer drug candidate and releasing it in presence of a reducing agent. This system shows a high entrapment efficiency with up to 15 mg drug per gram of peptide (5.8 mol‐%). Treatment of the NP s with reducing agent results in the disassembly of the NP s and release of the drug molecules. A reduction in cell viability is observed at drug concentrations above 250 n m in HEK 293T and HeLa cell lines. This drug delivery system has potential for targeting tumor sites via the EPR effect while taking advantage of the increased reduction potential in tumor microenvironment.